Namhlanje i-sanofi-aventis Canada Inc. (i-Sanofi) ibhengeze imvume ye-Libtayo® (cemiplimab) yonyango lwabaguli abadala abanomhlaza womlomo wesibeleko abaye baqhubela phambili okanye emva kwe-chemotherapy esekelwe kwi-platinum kwaye bafuna unyango olongezelelweyo lwenkqubo ukunyanga ukuphindaphinda okanye i-metastatic. isifo. Ukwamkelwa kusekelwe kwiSigaba se-3 UKUMNZA-Isibeleko soFundo lwe-1 se-Cemiplimab kubantu abadala abane-Cancer Cervical (NCT03257267). Ulingo, olwalulolona lingo lwezonyango olungazange lwenzeke ngaphambili kumhlaza womlomo wesibeleko olukwinqanaba eliphezulu, luquke izigulane ezinomhlaza womlomo wesibeleko ophindaphindiweyo okanye we-metastatic apho histology yayiyi-squamous cell carcinoma okanye i-adenocarcinoma. Abathathi-nxaxheba baye bahlelwa ukuba bafumane i-cemiplimab okanye ukhetho lomphandi lwe-chemotherapy. Esona siphelo siphambili solingo yayikukusinda kukonke.
Mark Surka, Ph.D, Oncology Medical Head, Sanofi Canada: “Ngelixa amazinga omhlaza womlomo wesibeleko eCanada ebulela ngombulelo, ngenxa yenxalenye enkulu yokusebenza kwesitofu sokugonya se-HPV ekuthinteleni umhlaza wangaphambi komlomo wesibeleko ukuba ungabikho, iCanada isabona i-1400. abasetyhini abafunyaniswa benesi sifo minyaka le kwaye bafuna iindlela zonyango. Siyazingca ngokuzisa i-Libtayo ukuba ivunywe kwabasetyhini abafunyaniswa benomhlaza womlomo wesibeleko ophindaphindiweyo okanye we-metastatic, kunye nabasebenzi bezempilo ababanyangayo. ”
Isalathiso sesine seLibtayo kubunzima bokunyanga umhlaza
Ngesibhengezo sanamhlanje, i-Libtayo ngoku yamkelwe njengokhetho lwe-immunotherapy kwii-cancer ezine eziphambili:
• Ngo-Epreli ka-2019, i-Libtayo ibe lukhetho lokuqala lonyango lwe-immunotherapy e-Canada kubantu abadala abane-metastatic okanye indawo ephucukileyo ye-cutaneous squamous cell carcinoma (CSCC) abangabagqatswa botyando olunyangayo okanye ukunyanga ngemitha.
• Ngo-Okthobha ka-2021, ukufumaneka kwe-Libtayo kwandiswe ukubandakanya abantu abadala abanomhlaza wemiphunga weseli ongeyonxalenye encinci echaza i-PD-L1 kwi-≥ 50% yeeseli zethumba (i-Tumour Proportion Score [TPS] ≥ 50%), njengoko kugqitywe ngokuqinisekiswa uvavanyo, kungabikho EGFR, ALK okanye ROS1 aberrations abaye NSCLC lwasekuhlaleni phambili abangabaviwa utyando resection okanye chemoradiation definitive, okanye metastatic NSCLC.
• Kwakhona ngo-Okthobha we-2021, i-Libtayo yavunywa kunyango lwabantu abadala abane-basal cell carcinoma yendawo (BCC) eyayiphathwa ngaphambili nge-hedgehog pathway inhibitor (HHI).
INTO ONOKUYITHATHA KWELI NQAKU:
- In October 2021, the availability of Libtayo was expanded to include adults with advanced non-small cell lung cancer expressing PD-L1 in ≥ 50% of tumour cells (Tumour Proportion Score [TPS] ≥ 50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC.
- (Sanofi) announced the approval of Libtayo® (cemiplimab) for the treatment of adult patients with cervical cancer who have progressed on or after prior platinum-based chemotherapy and who require additional systemic therapy to treat recurrent or metastatic disease.
- “While rates of cervical cancer in Canada are thankfully decliningii, due in large part to the effectiveness of the HPV vaccine in preventing cervical pre-cancers from formingiii, Canada still sees 1400 women diagnosed with this disease every yeariv and who need treatment options.
